



# Evolve Global Healthcare Enhanced Yield Fund


LIFE invests in top global healthcare companies, with the added value of a covered call strategy applied on up to 33% of the portfolio. Covered call options have the potential to provide extra income and help hedge long stock positions.

**ETF TICKERS:** LIFE (HEDGED); LIFE.B (UNHEDGED); LIFE.U (USD)  
**MUTUAL FUND FUNDSERV CODE:** EVF170 (Class F); EVF171 (Class A)


## General Industry Update

The global pharmaceutical industry is expected to continue to grow as the largest pharma companies are front and center in the fight against COVID-19. The **US accounts for over 46% of the global pharmaceutical market** and is home to 6 of the top 10 largest pharmaceutical companies. Companies with successful COVID-19 drugs are leading the pack on revenue growth.<sup>1</sup>

North America



Europe



The use of medical robots continues to grow as hospitals strive to increase efficiencies and accuracies in patient care. The **global medical robots** market size is expected to grow at a **CAGR of 144% by 2027**. **Intuitive Surgical** and **Stryker** are two companies that are leaders in the space and positioned to benefit from this growth.<sup>2</sup>



## Pfizer Inc

At the beginning of the month **Pfizer** announced it would be buying Canadian biotechnology company **Trillium Therapeutics** for **US \$2.26 Billion**. Trillium Therapeutics develops innovative therapies for cancer treatment. This is the second largest deal for a Canadian Biotech company after Shire Pharmaceuticals Group purchased AIDS drug developer BioChem Pharma for CAD\$5.9 billion 20 years ago.<sup>4</sup>

News relating to Pfizer's COVID-19 vaccine continued into September as Pfizer and Moderna vaccines both got full Health Canada approval.<sup>5</sup> Pfizer and BioNTech submitted initial trial data for the vaccine in children aged 5 to 11. The firm is seeking emergency use authorization.<sup>6</sup> The FDA agreed to back Pfizer's booster shot for senior citizens and high-risk individuals.<sup>7</sup> Also this month, Pfizer launched a study testing an oral antiviral COVID-19 drug and announced the beginning of a trial testing a flu vaccine based on messenger-RNA.<sup>7,8</sup>



## Novartis AG

In September, **Novartis** signed a deal with Britain's healthcare service provider for the use of the new anti-cholesterol drug called Leqvio. The company expects the drug to be a top seller and treat 300,000 patients over the next three years<sup>10</sup>

## Stryker Corp

**Stryker** announced the acquisition of **Gauss Surgical**, a medical device company. Gauss's flagship product is Triton, which is an AI-enabled platform for real time monitoring of blood loss during surgery. Triton combines AI with the simplicity of mobile devices.<sup>11</sup>

**Triton synchronizes hemorrhage intervention with integrated protocols and alerts.**

[Power your hemorrhage protocol >](#)



## AstraZeneca PLC

**AstraZeneca** is partnering with Imperial College London to research next generation messenger RNA technology that can fight cancer and other diseases such as respiratory illnesses.<sup>12</sup>

## PERFORMANCE ATTRIBUTION:

For the month, AstraZeneca Plc made the biggest contribution to the Fund, followed by Thermo Fisher Scientific Inc.

## PERFORMANCE (%)

TOTAL RETURNS*	1 MTH	YTD	1 YR	2 YR	3 YR	SI**
LIFE (HEDGED)	-5.45	11.86%	14.27	14.45	11.40	10.00
LIFE.B (UNHEDGED)	-5.69	9.61%	9.01	13.71	11.17	11.45
LIFE.U (USD)	-6.06	10.15%	14.60	-	-	13.60

Source: Bloomberg, as at September 30, 2021. \*\* Performance since inception of LIFE and LIFE.B on October 24, 2017 and LIFE.U on November 27, 2019.

### SOURCES:

- <https://www.visualcapitalist.com/worlds-biggest-pharmaceutical-companies/>
- Medical Robots Market to Witness Growth Acceleration | Omnicell, Inc., Intuitive Surgical – Bulk Solids Handling (bulk-solids-handling.com)
- <https://www.docwirenews.com/future-of-medicine/top-5-robotic-surgery-systems/>
- <https://www.theglobeandmail.com/business/article-pfizer-set-to-swallow-canadian-cancer-drug-developer-trillium/>
- <https://globalnews.ca/news/8195443/covid-coronavirus-vaccine-12-kids-pfizer-moderna/>
- <https://www.cbc.ca/news/health/pfizer-biontech-us-fda-covid-vaccine-children-1.6191807>
- <https://apnews.com/article/science-health-coronavirus-pandemic-coronavirus-vaccine-203d8c288858e815175880753cbc9b8f>
- <https://globalnews.ca/news/8223650/pfizer-study-oral-covid-drug/>
- <https://www.thehindu.com/sci-tech/science/pfizer-begins-study-of-mrna-flu-vaccine/article36705770.ece>
- <https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-signs-deal-with-britains-nhs-new-cholesterol-drug-leqvio-2021-08-31/>
- <https://hitconsultant.net/2021/09/07/stryker-acquires-gauss-surgical/#.YVXSyTHMKU>
- <https://www.bloomberg.com/news/articles/2021-09-23/astazeneca-to-help-develop-imperial-s-new-rna-technology>

Commissions, trailing commissions, management fees and expenses all may be associated with exchange traded mutual funds (ETFs) and mutual funds. Please read the prospectus before investing. ETFs and mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. There are risks involved with investing in ETFs and mutual funds. Please read the prospectus for a complete description of risks relevant to the ETF and mutual fund. Investors may incur customary brokerage commissions in buying or selling ETF and mutual fund units. This communication is intended for informational purposes only and is not, and should not be construed as, investment and/or tax advice to any individual.

The indicated rates of return are the historical annual compound total returns net of fees (except for figures of one year or less, which are simple total returns) including changes in per unit value and reinvestment of all dividends or distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. The rates of return shown in the table are not intended to reflect future values of the ETF or returns on investment in the ETF. ETFs are not guaranteed, their values change frequently, and past performance may not be repeated.

Certain statements contained in this documentation constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to a future outlook and anticipated distributions, events or results and may include statements regarding future financial performance. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “anticipate”, “believe”, “intend” or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Evolve undertakes no obligation to update publicly or otherwise revise any forward-looking statement whether as a result of new information, future events or other such factors which affect this information, except as required by law.